Frost & Sullivan Independent Equity Research

Kadimastem offers treatment of diabetes and neurological diseases such as ALS by cellular therapy; Company is pursuing clinical trial (ALS), and pre-clinical processes (diabetes); target price set at NIS 0.85


Company: Kadimastem        

Sector: Biotechnology

Report type: Initiation of Coverage

Published on: 12 June, 2018

Kadimastem research articles:

Close Menu
Font Resize